21 19. Duncan MS, Vasan RS, Xanthakis V. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years. J Am Heart Assoc. 2019;8:e011433. doi: 10.1161/ JAHA.118.011433 20. Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G. Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). J Am Heart Assoc. 2016;5. doi: 10.1161/JAHA.115.003012 21. Anchouche K, Baass A, Thanassoulis G. Lp(a): A Clinical Review. Clin Biochem. 2025 Jun;137:110929. doi: 10.1016/j. clinbiochem.2025.110929 22. Bhatia HS, Wandel S, Willeit P, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein CholesterolMediated Cardiovascular Risk: A Participant-Level Meta-Analysis. 2025 Jan 28;151(4):312-321. doi: 10.1161/ CIRCULATIONAHA.124.069556 23. Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88. doi: 10.3389/ fcvm.2020.00088 24. Koschinsky ML, Boffa MB. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis. 2022;349:92-100. doi: 10.1016/j. atherosclerosis.2022.04.001 25. Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022;349:72-81. doi: 10.1016/j. atherosclerosis.2022.04.009 26. Bansal A, Cho L. Prevalence of Lipoprotein(a) Testing in a Contemporary Cohort. Circulation. 2025 Mar 4;151(9):649651. doi: 10.1161/CIRCULATIONAHA.124.070361 27. Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13:894-900. doi: 10.1016/j.jacl.2019.09.010 28. Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol. 2016;36:2019-2027. doi: 10.1161/ATVBAHA.116.307983 29. Greco A, Finocchiaro S, Spagnolo M, Faro DC, Mauro MS, Raffo C, Sangiorgio G, Imbesi A, Laudani C, Mazzone PM, Ammirabile N, Giacoppo D, Landolina D, Capodanno D. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation. 2025 Feb 11;151(6):400415. doi: 10.1161/CIRCULATIONAHA.124.069210 30. FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol. U.S. Food & Drug Administration News & Events 31. Nicholls SJ. Therapeutic Potential of Lipoprotein(a) Inhibitors. Drugs. 2024;84:637-643. doi: 10.1007/s40265-02402046-z 32. Doerfler AM, Park SH, Assini JM, et al. LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study. 2022 Oct 13:27:337-351. doi: 10.1016/j.omtm.2022.10.009 33. Chuecos MA, Park SH, Bhakta MM, et al. Cytosine base editing of LPA in transgenic mice averts large deletions. 2026 Jun 3;34(6):3334-3352. doi: 10.1016/j.ymthe.2026.02.049. 34. Gurevitz C, Bajaj A, et al. Gene Therapy and Genome Editing for Lipoprotein Disorders. doi. 10.1093/eurheart/ehaf411
RkJQdWJsaXNoZXIy MjI2NjI=